secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-09-04T12:30:05+00:00
Accession:  0001193125-26-382838
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics receives Nasdaq delisting notice after negative stockholders' equity
--------------------------------------------------------------------------------

- On Aug 31, 2026, Nasdaq notified QNCX that stockholders' equity was ($35.3M) as of June 30, 2026, below $10M minimum.
- Company has until Oct 15, 2026 to submit compliance plan; Nasdaq may grant extension to Feb 27, 2027.
- Shares continue trading on Nasdaq Global Select under QNCX; no immediate delisting effect.
- Filed initial listing application to move to Nasdaq Capital Market; may rename to IRulya Therapeutics Inc. under IRLA.
- Management evaluating alternatives; no assurance of regaining compliance or listing approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526382838/0001193125-26-382838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526382838/d105528d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-382838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer